- Home
- GILD
GILD
Gilead Sciences Inc.
as 07-26-2024 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 90.4B | IPO Year: | 1992 |
| Target Price: | $82.81 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.35 | EPS Growth: | -92.10 |
| 52 Week Low/High: | $62.07 - $87.87 | Next Earning Date: | 08-08-2024 |
| Revenue: | $27,450,000,000 | Revenue Growth: | 1.51% |
| Revenue Growth (this year): | 3.78% | Revenue Growth (next year): | 1.27% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parsey Merdad | GILD | Chief Medical Officer | Jul 1 '24 | Sell | $68.63 | 2,000 | $137,260.00 | 96,380 | SEC Form 4 |
| Parsey Merdad | GILD | Chief Medical Officer | Apr 1 '24 | Sell | $72.96 | 2,000 | $145,920.00 | 96,304 | SEC Form 4 |
| Parsey Merdad | GILD | Chief Medical Officer | Feb 28 '24 | Sell | $73.18 | 2,000 | $146,360.00 | 100,936 | SEC Form 4 |
| GILEAD SCIENCES, INC. | GILD | 10% Owner | Jan 29 '24 | Buy | $21.00 | 15,238,095 | $319,999,995.00 | 30,061,124 | SEC Form 4 |
| Dickinson Andrew D | GILD | Chief Financial Officer | Jan 16 '24 | Sell | $85.78 | 5,000 | $428,900.00 | 101,534 | SEC Form 4 |
| Mercier Johanna | GILD | Chief Commercial Officer | Jan 9 '24 | Sell | $85.23 | 8,242 | $702,465.66 | 82,729 | SEC Form 4 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Business Wire
a day ago
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Motley Fool
2 days ago
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
MT Newswires
2 days ago
Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study
Business Wire
3 days ago
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
Benzinga
3 days ago
Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire
Clinical Trials Arena
4 days ago
ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial
Medical Device Network
4 days ago
Nanotechnology in medicine: Who are the leading public companies?
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.